Alexei Marko - Neovasc CEO, Director

G5Z1 -- Germany Stock  

EUR 0.02  0.00  0.00%

Mr. Alexei Marko is Director of Neovasc Inc. Mr. Markos 18 years of experience in the medical device field spans product development, sales and marketing and executive management. Mr. Marko has held management positions with Neovasc predecessor companies since 1999 and assumed the role of CEO in 2008 in conjunction with the companys expansion and restructuring. Mr. Marko was appointed to the Companys board of directors on June 12, 2003 and is a resident of British Columbia, Canada. In October 2007, Mr. Marko was appointed President and Chief Operating Officer of Medical Ventures Corporationration, a predecessor company. Previously, Mr. Marko was the Vice President and Chief Operating Officer and Vice President, Development and Engineering of MEV. Mr. Marko is a listed inventor on a number of issued or pending patents related to medical technologies. He is also a registered professional engineer, and sits on the board of directors for the Medical Device Development Centre in Vancouver. In 2005, he was named one of Business in Vancouvers Top Forty Under 40 in recognition of his achievements
Age: 42  CEO Since 2018      
Marko completed both his B.A.Sc. at Queen?s University and an M.A.Sc. in electrical engineering at the University of British Columbia, specializing in medical device development. He is a registered professional engineer

Management Efficiency

The company has return on total asset (ROA) of (32.56) % which means that it has lost $32.56 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (575.51) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 24.19M in total debt. Neovasc has Current Ratio of 3.33 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. Neovasc is traded on Frankfurt Stock Exchange in Germany.Neovasc (G5Z1) is traded on Frankfurt Stock Exchange in Germany and employs 110 people.

Neovasc Leadership Team

Vicki Bebeau, Vice President - Clinical Affairs
Brian McPherson, COO
Fred Colen, President CEO
Steven Rubin, Independent Director
William ONeill, Independent Director
Christopher Clark, CFO, Corporate Secretary
Alexei Marko, CEO, Director
Douglas Janzen, Independent Director
Jane Hsiao, Independent Director
Randy Lane, Vice President - Research & Development
Paul Geyer, Chairman of the Board

Stock Performance Indicators

Current Sentiment - G5Z1

Neovasc Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Neovasc. What is your trading attitude regarding investing in Neovasc? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.